Guggenheim analyst Yatin Suneja raised the firm’s price target on Immunovant (IMVT) to $44 from $41 and keeps a Buy rating on the shares. The firm adjusted its model following Q4 earnings.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMVT:
- Advancing a Differentiated FcRn Pipeline: Late-Stage Catalysts and Solid Fundamentals Support Buy Rating on Immunovant
- Immunovant reports Q3 EPS (61c), consensus (70c)
- Is IMVT a Buy, Before Earnings?
- Apellis, Olema, Exicure, Immunovant, LivePerson Insider Shake-Up
- Immunovant price target raised to $22 from $16 at Truist